CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Synthorx, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Synthorx, Inc.
11099 North Torrey Pines Road
Suite 190
Phone: (858) 750-4700p:858 750-4700 La Jolla, CA  92037-1029  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 1/23/2020.
This company ceased filing statements with the SEC on 2/3/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board PratikShah 49 12/19/2018 10/1/2018
President, Chief Executive Officer, Director Laura K.Shawver 61 11/1/2017 11/1/2017
Acting Chief Financial Officer TigheReardon 7/1/2018 7/1/2018
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 48 (As of 9/30/2019)
Outstanding Shares: 32,337,776 (As of 10/31/2019)
Stock Exchange: NASD
Federal Tax Id: 464709185
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023